8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): October 11, 2016 (October 11, 2016)

Patheon N.V.

(Exact Name of Registrant as Specified in its Charter)

The Netherlands	2834	98-1153534
(State or Other Jurisdiction of Incorporation)	(Primary Standard Industrial Classification Code Number)	(IRS Employer Identification No.)

Herengracht 483

1017BT, Amsterdam

The Netherlands

+31 (0)20 622 3243

(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)

Eric Sherbet

General Counsel and Secretary

111 Speen St, Suite 550

Framingham, Massachusetts 01701

(508) 620-2510

(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent For Service)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02(b) Departure of Directors or Certain Officers

On October 11, 2016, Patheon N.V. (the “Company”) issued a press release announcing that its Executive Vice President and Chief Financial officer, Mr. Stuart Grant, plans to retire in 2017. Mr. Grant will remain in his current role until a successor has been appointed and a transition has been completed. The text of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01Financial Statements and Exhibits.

(d)   Exhibits.  The following exhibits are being filed herewith:

No.	Description
99.1	Press Release dated October 11, 2016

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PATHEON N.V.
By:	/s/ Eric Sherbet
Name:	Eric Sherbet
Title:	Secretary and General Counsel

Date: October 11, 2016

EXHIBIT INDEX

Exhibit No.		Description
99.1	Press Release, dated October 11, 2016.

EX-99.1

Patheon Announces the Retirement of Stuart Grant

Company Commences Search for a New CFO

DURHAM, N.C. — October 11, 2016 – Patheon N.V. (NYSE:PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industries, today announced that its executive vice president and chief financial officer, Stuart Grant, plans to retire in 2017. Grant will remain in his current role until a successor has been appointed and a transition has been completed. The company has initiated a search to identify a replacement for Grant.

“We’re very grateful to Stuart for his significant contributions to the success of Patheon,” said Jim Mullen, chief executive officer, Patheon. “Stuart has been a great leader, colleague and friend. We wish him all the best in his well-deserved retirement.”

Grant added,” I’ve been honored to be part of a great team at Patheon and look forward to assisting the company with the search and transition process.”

Forward-looking Statements

The statements in this press release that are not historical facts may be forward-looking statements. Such forward looking statements, based upon the current beliefs and expectations of Patheon's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward looking statements. Accordingly, readers should not place undue reliance on forward-looking statements as a prediction of actual results.

About Patheon

Patheon is a leading global provider of pharmaceutical development and manufacturing services. With approximately 8,000 employees worldwide, Patheon provides a comprehensive, integrated and highly customizable set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. www.patheon.com

###

Contact:

Mari Mansfield
Tel: +1 (919) 226 -3137
Email: Mari.Mansfield@Patheon.com

media@patheon.com